In addition to the quantity of immune cells, the activity of immunoregulatory signalling pathways, such as the co-inhibitory pathway of programmed death ligand 1 (PD-L1, CD274) and its receptor programmed death 1 (PD-1, PDCD1), may affect cancer progression. This evidence concerns the gene PDCD1 and cancer.